about
Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer cellsThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practiceShort-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trialProfile of V. Craig JordanUsing gene expression signatures to identify novel treatment strategies in gulf war illnessTransporting antitumor drug tamoxifen and its metabolites, 4-hydroxytamoxifen and endoxifen by chitosan nanoparticlesPharmGKB: understanding the effects of individual genetic variantsUsing large-scale molecular data sets to improve breast cancer treatment.Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis.Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifenAcquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populationsModeling time-dependent transcription effects of HER2 oncogene and discovery of a role for E2F2 in breast cancer cell-matrix adhesionThe molecular genomics of metastatic brain tumours.Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenMetabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversyTamoxifen non-estrogen receptor mediated molecular targets.Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time.Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer studyThe new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer.Breast Cancer Patients Have Greatly Benefited from the Progress in Molecular Oncology.Progress in endocrine approaches to the treatment and prevention of breast cancerThe St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations.The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.By looking back we can see the way forward: enhancing the gains achieved with antihormone therapyPotential of selective estrogen receptor modulators as treatments and preventives of breast cancer.miRNA clusters as therapeutic targets for hormone-resistant breast cancer.Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.Letrozole.Cancer stem cells in the human mammary gland and regulation of their differentiation by estrogen.Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.Therapeutic drug monitoring of targeted anticancer therapy.Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.
P2860
Q24594804-FF77B771-77A9-4071-82A5-AEFB99972A72Q26830744-EEAA1996-EF40-402D-909A-0043D0B5E25EQ27009177-E8FBC4ED-D504-404D-BBA7-CB3A5F9C7445Q28253151-347EA8DF-A35C-473F-B67A-8F264C147CDCQ28397964-79BFC4B5-E6E1-4B98-9538-871D58804621Q28488379-797BF852-DAE9-4361-B109-D7AB8CAAA461Q28754550-5E9A7BDC-7B41-43E8-89E4-2A03D89AF5DAQ30656126-95AEE7D1-B5F1-4FD1-92C5-3FFBA2429B37Q33823065-565DC367-F528-437E-8633-1EF6D945DBC8Q33841512-ADB900E4-E31C-4D45-A5D7-3CCD5EF4A629Q33841524-B40F03C0-8199-4F14-9750-B4E05259873EQ34315889-7A35FFAC-A879-4B40-91B3-7132348D05A2Q34360155-4CF7B2A7-D8FC-471A-9432-876E55FC7C07Q34499855-46298108-FEA3-4DB9-A39C-3B8E3B084558Q34736075-DCEB73BC-06E0-4935-B2B2-A58F04DF7958Q34736986-23649F2D-78DD-445A-80DC-178224CA4744Q35006860-C457AB4F-79FA-4921-9BCC-014A3957BD8EQ35056229-33508FA6-3FE3-4F71-9DD1-AD4619133598Q35569331-8E76E4B8-84E0-42C7-A1F9-AAFA79B9B2DCQ35571438-645130B0-597C-4104-BF75-2B3CB286B475Q35690804-AA417D1F-1533-49E9-98F4-4E9A0DF2C050Q35827822-43E32D48-5F1F-4734-A0DD-01E2AF37CB81Q36113804-169F9CE9-F395-4CAD-8D8F-1A00A2625966Q36147954-BF89367A-8B71-4F14-8CC5-42AD345DCEAAQ36457511-55CDB1D9-0226-44E1-8D8D-97C9AAD2224CQ36464743-1E7606E2-D5D1-4BC6-82E3-33875DF6C6ECQ36517144-4E95DFB6-8A66-4E2E-8890-372C36243FF9Q36598699-EAED2620-B341-4BAD-8801-DD963E724AC6Q37039782-C2DB22DE-8630-40AF-835F-C5A307D1F44DQ37156496-601DFD1D-1E15-4AFA-9070-08A868DB2386Q37316805-92510E2F-85E2-41AF-9319-62CF0816C9C1Q37375092-92EDD72E-0CC0-442D-A67A-1DE2607ABE02Q37376013-87040AA6-67ED-4742-9BAF-9B3C5FCE7E4FQ37678053-5AA37108-8938-4955-A2B7-87FE7A49F6FDQ37679903-718CF443-1039-4CE6-BA8D-A31B49370CDAQ37913359-ED00B80A-14AD-4233-8E14-8ED5C8820A3BQ38255064-73E29751-9F40-4C34-94C1-1FBCED4A51F4Q38319572-C640FA29-EC22-42D1-A416-380533D816DDQ38579278-C2FE9C65-B712-4493-BE8A-5BC26CC9C68AQ38604479-32001878-2838-459B-94D4-02458B4747F1
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Tamoxifen: catalyst for the change to targeted therapy
@ast
Tamoxifen: catalyst for the change to targeted therapy
@en
Tamoxifen: catalyst for the change to targeted therapy
@nl
type
label
Tamoxifen: catalyst for the change to targeted therapy
@ast
Tamoxifen: catalyst for the change to targeted therapy
@en
Tamoxifen: catalyst for the change to targeted therapy
@nl
prefLabel
Tamoxifen: catalyst for the change to targeted therapy
@ast
Tamoxifen: catalyst for the change to targeted therapy
@en
Tamoxifen: catalyst for the change to targeted therapy
@nl
P2860
P3181
P1476
Tamoxifen: catalyst for the change to targeted therapy
@en
P2093
V Craig Jordan
P2860
P3181
P356
10.1016/J.EJCA.2007.11.002
P407
P577
2008-01-01T00:00:00Z